
## Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

Ira Jacobs, Danielle Petersel, Lesley G. Shane, Chee-Keng Ng, Carol Kirchhoff, Gregory Finch, Sadiq Lula

Corresponding author: Ira Jacobs: Pfizer Essential Health, Pfizer Inc. 235 East 42nd Street, New York, NY, 10017-5755, USA, Email: ira.iacobs@pfizer.com

## **Supplementary Fig. S2** Downs and Black score of full-text observational studies (6 studies): oncology<sup>1,2</sup> and chronic inflammatory disease<sup>3-6</sup> studies.



## References

- 1. Roy PS, et al. Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol. 2013;34(4):292.
- 2. Thakral P, et al. An approach for conjugation of 177Lu-DOTA-SCN-rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients. Indian J Med Res. 2014;139(4):544.
- 3. Roshique KK, Ravindran V. Efficacy and safety of a biosimilar rituximab in biologic naive patients with active rheumatoid arthritis. Clin Rheumatol. 2015;34(7):1289-92.
- 4. Farkas K, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257-62.
- 5. Jung YS, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705-12.
- 6. Kang Y-S, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951-6.